2021
Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient group
2019
Clinical outcome indicators in chronic hepatitis B and C: A primer for value‐based medicine in hepatology
Strazzabosco M, Cortesi P, Conti S, Okolicsanyi S, Rota M, Ciaccio A, Cozzolino P, Fornari C, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Zavaglia C, Perricone G, Munari L, Mantovani L, Belli L. Clinical outcome indicators in chronic hepatitis B and C: A primer for value‐based medicine in hepatology. Liver International 2019, 40: 60-73. PMID: 31654608, PMCID: PMC10916792, DOI: 10.1111/liv.14285.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsCarcinoma, HepatocellularFemaleGastroenterologyHepatitis B, ChronicHepatitis C, ChronicHumansItalyLiver CirrhosisLiver NeoplasmsLongitudinal StudiesMaleMiddle AgedProspective StudiesQuality Indicators, Health CareSurvival AnalysisTreatment OutcomeValue-Based Health InsuranceConceptsClinical outcome indicatorsClinical practiceOutcome indicatorsChronic hepatitis BClinical practice settingMajor health problemCurrent international guidelinesNew effective treatmentsValue of careMETHODS/RESULTSHCV patientsHCV infectionHepatitis BClinical outcomesLiver diseaseMulticentre studyEffective treatmentHealth problemsInternational guidelinesCare deliveryValue-based medicineCostly treatmentPractice settingsHBVPatientsDiagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Ippolito D, Querques G, Pecorelli A, Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Journal Of Computer Assisted Tomography 2019, Publish Ahead of Print: &na;. PMID: 30407241, DOI: 10.1097/rct.0000000000000807.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaProgressive diseasePartial responseDynamic contrast-enhanced perfusionPerfusion CT valuesHepatic perfusion indexResponse Evaluation CriteriaMultifocal hepatocellular carcinomaIntravenous bolus injectionBlood flow changesContrast-enhanced perfusionRow Computed TomographyPerfusion CT techniquesStandard of referenceNonprogressor groupProgressor groupSorafenib administrationCirrhotic patientsArterial perfusionHepatic perfusionPD patientsTumor responsePerfusion indexTherapeutic response
2018
Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions
Ippolito D, Querques G, Okolicsanyi S, Franzesi C, Pecorelli A, Lombardi S, Orsini E, Strazzabosco M, Sironi S. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions. European Journal Of Radiology 2018, 106: 62-68. PMID: 30150052, DOI: 10.1016/j.ejrad.2018.07.012.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaAnti-angiogenic therapyPerfusion CT imagingHepatocellular carcinomaPerfusion parametersProgressor groupSurvival rateNon-progressor groupOverall survival rateKaplan-Meier analysisAssessment of responseAntiangiogenetic treatmentCirrhotic patientsSorafenib administrationPrognostic indicatorTumor responseTarget lesionsHCC lesionsIndividualized treatmentTumor neoangiogenesisPatientsOverall populationHigher survival rateCT imagingSurvival predictionThe optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Cortesi P, Belli L, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani L, Strazzabosco M, Association T. The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDCC patientsTreatment strategiesIntestine Transplant AssociationProgression of HCVTransplant-eligible patientsHepatitis C therapyTransplant-related factorsCohort of patientsTime of transplantationDecision analytical modelCost-effectiveness analysisDAA effectivenessDAA treatmentEuropean LiverHCC presencePre-LTMELD scoreC therapyCirrhotic patientsDisease recurrenceTransplant centersSpecific regimenTransplant AssociationPatient level
2017
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine
Carbone M, Cristoferi L, Cortesi PA, Rota M, Ciaccio A, Okolicsanyi S, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Belli LS, Munari LM, Mantovani L, Strazzabosco M. Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2017, 1864: 1415-1422. PMID: 28844954, DOI: 10.1016/j.bbadis.2017.08.025.Peer-Reviewed Original ResearchConceptsClinical outcome indicatorsAutoimmune liver diseaseLiver diseaseMajor autoimmune liver diseasesTertiary clinical centersPrimary sclerosing cholangitisPrimary biliary cholangitisDifferent clinical outcomesNatural history studiesValue of careAutoimmune hepatitisClinical practice environmentJesus BanalesMarco MarzioniNicholas LaRussoPeter JansenSclerosing cholangitisBiliary cholangitisConsecutive patientsClinical outcomesMedian timeCare pathwayClinical centersClinical strategiesValue-based medicineDirect‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis
Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, Rota M, Cesana G, Mantovani LG, Annoni G, Strazzabosco M. Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis. Liver International 2017, 37: 982-994. PMID: 27943549, DOI: 10.1111/liv.13339.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntiviral AgentsComputer SimulationCost-Benefit AnalysisDecision Support TechniquesDisease ProgressionDrug CostsDrug Therapy, CombinationFemaleFrail ElderlyGeriatric AssessmentHepatitis C, ChronicHumansLiver CirrhosisMaleMarkov ChainsModels, EconomicQuality-Adjusted Life YearsRisk FactorsTime FactorsTreatment OutcomeConceptsIncremental cost-effectiveness ratioChronic hepatitis CQuality-adjusted life yearsCost-effectiveness ratioElderly patientsCHC patientsHepatitis CFrailty phenotypeFrailty statusFibrosis stageLife yearsElderly CHC patientsMild fibrosis stageInterferon-free treatmentHealthcare system perspectiveLifetime time horizonCost-effectiveness analysisDAA treatmentDAA combinationsAdvanced fibrosisFrail subjectsClinical variablesLiver fibrosisF2 patientsAge 75
2015
Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis
Cortesi P, Mantovani L, Ciaccio A, Rota M, Mazzarelli C, Cesana G, Strazzabosco M, Belli L. Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. American Journal Of Transplantation 2015, 15: 1817-1826. PMID: 26086300, PMCID: PMC4946849, DOI: 10.1111/ajt.13320.Peer-Reviewed Original Research
2014
Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options
Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M. Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options. Journal Of Viral Hepatitis 2014, 22: 175-183. PMID: 25040391, PMCID: PMC4519006, DOI: 10.1111/jvh.12278.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioEnd-stage liver diseaseCost-effectiveness analysisF3-F4Liver diseaseChronic hepatitis C genotype 1 patientsHepatitis C genotype 1 patientsItalian National Health System perspectiveNational Health System perspectiveResponse-guided therapyGenotype 1 patientsMETAVIR fibrosis stageHealth system perspectiveQuality-adjusted life yearsPatient selection strategiesCost-effectiveness ratioG1 patientsNaive patientsTriple therapyOnly patientsAdvanced fibrosisFuture regimensMore regimensTreatment optionsFibrosis stageA Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study
Angelico M, Nardi A, Romagnoli R, Marianelli T, Corradini SG, Tandoi F, Gavrila C, Salizzoni M, Pinna AD, Cillo U, Gridelli B, De Carlis LG, Colledan M, Gerunda GE, Costa AN, Strazzabosco M, Investigators L, Committee: L, Angelico M, Cillo U, Fagiuoli S, Strazzabosco M, Board: A, Caraceni P, Toniutto P, Board: C, Costa A, Investigators: P, Salizzoni T, Romagnoli R, Bertolotti G, Patrono D, De Carlis L, Slim A, Mangoni J, Rossi G, Caccamo L, Antonelli B, Mazzaferro V, Regalia E, Sposito C, Colledan M, Corno V, Tagliabue F, Marin S, Cillo U, Vitale A, Gringeri E, Donataccio M, Donataccio D, Baccarani U, Lorenzin D, Bitetto D, Valente U, Gelli M, Cupo P, Gerunda G, Rompianesi G, Pinna A, Grazi G, Cucchetti A, Zanfi C, Risaliti A, Faraci M, Tisone G, Anselmo A, Lenci I, Sforza D, Agnes S, Di Mugno M, Avolio A, Ettorre G, Miglioresi L, Vennarecci G, Berloco P, Rossi M, Corradini S, Molinaro A, Calise F, Scuderi V, Cuomo O, Migliaccio C, Lupo L, Notarnicola G, Gridelli B, Volpes R, Petri S, Zamboni F, Carbotta G, Dedola S, Collection and Verification and Biostatistics: D, Nardi A, Marianelli T, Gavrila C, Ricci A, Vespasiano F. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. Digestive And Liver Disease 2014, 46: 340-347. PMID: 24411484, DOI: 10.1016/j.dld.2013.11.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedBayes TheoremBody Mass IndexCohort StudiesCold IschemiaDelayed Graft FunctionEnd Stage Liver DiseaseFemaleGraft RejectionGraft SurvivalHumansItalyLiver TransplantationMaleMiddle AgedMultivariate AnalysisPrimary Graft DysfunctionProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsTissue DonorsTreatment OutcomeConceptsEarly graft lossGraft lossUnited NetworkLiver transplantationPrior upper abdominal surgeryDonor body mass indexProspective European cohortsUpper abdominal surgeryOrgan Sharing registryPrimary liver transplantCold ischaemia timeBody mass indexRisk indexRecipient creatinineBayesian Cox modelsLiver transplantPortal thrombosisAbdominal surgeryCardiac deathIschaemia timeMass indexDonor ageEuropean cohortOrgan SharingCox model
2012
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study
Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, Pinna AD, Avolio AW, Fagiuoli S, Burra P, Strazzabosco M, Costa AN, Investigators F. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study. Journal Of Hepatology 2012, 58: 715-723. PMID: 23201239, DOI: 10.1016/j.jhep.2012.11.025.Peer-Reviewed Original ResearchConceptsHBsAg-negative recipientsHBcAb-positive graftsGraft survivalGraft lossNegative recipientsHBcAb positivityLiver transplantationPositive graftsPositive donorsHepatitis B core antibody-positive donorsDe novo HBV hepatitisAntibody-positive donorsHBcAb-positive donorsHBsAg-positive recipientsPositive donor graftsMatched-cohort studyPortal vein thrombosisDeceased heartHBsAg positivityNegative graftsHBV hepatitisDonor graftsFirst transplantHazard ratioPositive recipients
2011
Nuclear expression of S100A4 calcium‐binding protein increases cholangiocarcinoma invasiveness and metastasization
Fabris L, Cadamuro M, Moserle L, Dziura J, Cong X, Sambado L, Nardo G, Sonzogni A, Colledan M, Furlanetto A, Bassi N, Massani M, Cillo U, Mescoli C, Indraccolo S, Rugge M, Okolicsanyi L, Strazzabosco M. Nuclear expression of S100A4 calcium‐binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology 2011, 54: 890-899. PMID: 21618579, PMCID: PMC3753582, DOI: 10.1002/hep.24466.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnimalsApoptosisBile Duct NeoplasmsBile Ducts, IntrahepaticCell MovementCell NucleusCell ProliferationCholangiocarcinomaFemaleHumansMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9MiceMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisPrognosisS100 Calcium-Binding Protein A4S100 ProteinsConceptsSurgical resectionCCA cellsNuclear expressionCCA patientsMetastatic propertiesSevere combined immunodeficiency miceTFK-1Time of surgeryRole of S100A4Log-rank testCombined immunodeficiency miceExpression of S100A4EGI-1 cellsHuman CCA cell linesPotential therapeutic targetMMP-9 secretionCCA cell linesHuman liver samplesCholangiocarcinoma invasivenessNuclear S100A4Severe prognosisPatient survivalPoor prognosisNeoplastic ductsImmunodeficiency mice
2010
Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor–recipient matching
Angelico M, Cillo U, Fagiuoli S, Gasbarrini A, Gavrila C, Marianelli T, Costa AN, Nardi A, Strazzabosco M, Burra P, Agnes S, Baccarani U, Calise F, Colledan M, Cuomo O, De Carlis L, Donataccio M, Ettorre GM, Gerunda GE, Gridelli B, Lupo L, Mazzaferro V, Pinna A, Risaliti A, Salizzoni M, Tisone G, Valente U, Rossi G, Rossi M, Zamboni F, Investigators O. Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor–recipient matching. Digestive And Liver Disease 2010, 43: 155-164. PMID: 21185796, DOI: 10.1016/j.dld.2010.11.002.Peer-Reviewed Original ResearchConceptsDonor risk indexObservational cohort studyHepatocellular carcinomaLiver transplantationCohort studyDonor ageVirus infectionDeceased heart-beating donorsHepatitis B core antibodyMedian cold ischaemia timeMedian donor risk indexProspective observational cohort studyEnd-stage liver diseaseHepatitis B virus infectionHepatitis C virus infectionLiver MatchDonor populationItalian transplant centersOlder donor ageViral-related cirrhosisB core antibodyC virus infectionStage liver diseaseB virus infectionHigh-risk donorsCholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma” committee of the Italian Association for the Study of Liver disease
Alvaro D, Bragazzi MC, Benedetti A, Fabris L, Fava G, Invernizzi P, Marzioni M, Nuzzo G, Strazzabosco M, Stroffolini T, committee F. Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma” committee of the Italian Association for the Study of Liver disease. Digestive And Liver Disease 2010, 43: 60-65. PMID: 20580332, DOI: 10.1016/j.dld.2010.05.002.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAgedBile Duct NeoplasmsBile Ducts, ExtrahepaticBile Ducts, IntrahepaticCholangiocarcinomaCholangiopancreatography, Endoscopic RetrogradeCholangiopancreatography, Magnetic ResonanceData CollectionDiarrheaFatigueFemaleHepatitis CHumansItalyJaundiceLiver CirrhosisMaleMiddle AgedNauseaTomography, X-Ray ComputedUltrasonographyVomitingWeight LossConceptsClinical characteristicsIH-CCAAsymptomatic presentationEH-CCACoexistence of cirrhosisCurative surgical treatmentTissue-proven diagnosisNational surveyCurative intentSurgical treatmentViral cirrhosisLiver diseaseOpen surgeryDiagnostic managementDiagnostic modalitiesCholangiocarcinoma casesCholangiocarcinomaYounger ageItalian AssociationCirrhosisDifferent imaging proceduresImaging proceduresDiagnosisTreatmentAgeGenetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C
Hov JR, Lleo A, Selmi C, Woldseth B, Fabris L, Strazzabosco M, Karlsen TH, Invernizzi P. Genetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C. Journal Of Hepatology 2010, 52: 712-717. PMID: 20347497, DOI: 10.1016/j.jhep.2009.11.029.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCholangitis, SclerosingChromosome MappingChromosomes, Human, Pair 6EuropeFemaleGene FrequencyHLA-B AntigensHLA-C AntigensHLA-DR AntigensHLA-DRB1 ChainsHumansInflammatory Bowel DiseasesItalyLiver CirrhosisMaleMicrosatellite RepeatsMiddle AgedReference ValuesRisk AssessmentYoung AdultConceptsPrimary sclerosing cholangitisSclerosing cholangitisHLA-DRB1Risk of PSCTNF-alpha -308GNatural killer cellsP-valueChi-square testHLA-C2PSC patientsKiller cellsTumor necrosisPSC pathogenesisT lymphocytesSignificant associationAbstractTextMICA locusHLA complexHLADRB1CholangitisUncorrected p-valueKIRFurther studiesAIMSPrediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria
De Giorgio M, Vezzoli S, Cohen E, Armellini E, Lucà MG, Verga G, Pinelli D, Nani R, Valsecchi MG, Antolini L, Colledan M, Fagiuoli S, Strazzabosco M. Prediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transplantation 2010, 16: 503-512. PMID: 20373461, DOI: 10.1002/lt.22039.Peer-Reviewed Original ResearchConceptsMilan criteriaProgression rateHepatocellular carcinomaRisk factorsObserved progression rateT2 patientsBarcelona Clinic Liver Cancer (BCLC) algorithmEnd-Stage Liver Disease exceptionOrgan allocationTumor persistence/recurrenceStage T2 patientsT2 hepatocellular carcinomaConsecutive HCC patientsProgression-free survivalChronic liver diseasePersistence/recurrenceDistinct natural historyTreatment of choiceBCLC guidelinesMELD scoreMELD exceptionsLocal therapyTransarterial chemoembolizationLiver diseaseTumor diameter
2008
Prognostic Prediction in Hepatocellular Carcinoma
Strazzabosco M, Cohen E, Emre S. Prognostic Prediction in Hepatocellular Carcinoma. Journal Of Clinical Gastroenterology 2008, 42: 221-223. PMID: 18223506, DOI: 10.1097/mcg.0b013e31815ed0a9.Peer-Reviewed Original ResearchMorphological and Functional Features of Hepatic Cyst Epithelium in Autosomal Dominant Polycystic Kidney Disease
Alvaro D, Onori P, Alpini G, Franchitto A, Jefferson DM, Torrice A, Cardinale V, Stefanelli F, Mancino MG, Strazzabosco M, Angelico M, Attili A, Gaudio E. Morphological and Functional Features of Hepatic Cyst Epithelium in Autosomal Dominant Polycystic Kidney Disease. American Journal Of Pathology 2008, 172: 321-332. PMID: 18202196, PMCID: PMC2312356, DOI: 10.2353/ajpath.2008.070293.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlotting, WesternCell ProliferationCiliaCyst FluidCystsEpitheliumEstradiolFemaleFluorescent Antibody TechniqueHumansImmunohistochemistryInsulin-Like Growth Factor ILiver DiseasesMaleMicroscopy, Electron, ScanningMiddle AgedPolycystic Kidney DiseasesReceptor, IGF Type 1Receptors, EstrogenConceptsAdult autosomal dominant polycystic kidney diseaseInsulin-like growth factor-1Autosomal dominant polycystic kidney diseaseDominant polycystic kidney diseaseEstrogen receptorCyst epitheliumPolycystic kidney diseaseCyst fluidCell nuclear antigenKidney diseaseGrowth hormone receptorHormone receptorsNuclear antigenHepatic cyst fluidHuman cyst fluidEpithelial cellsRole of estrogenGrowth factor-1ADPKD patientsEstrogen antagonismImmunohistochemical expressionLarge cystsSmall cystsTherapeutic strategiesMTS proliferation
2007
Inheritance of hyperbilirubinemia: Evidence for a major autosomal recessive gene
Clementi M, Di Gianantonio E, Fabris L, Forabosco P, Strazzabosco M, Tenconi R, Okolicsanyi L. Inheritance of hyperbilirubinemia: Evidence for a major autosomal recessive gene. Digestive And Liver Disease 2007, 39: 351-355. PMID: 17347060, DOI: 10.1016/j.dld.2006.12.019.Peer-Reviewed Original Research
1991
Effect of Silibinin on biliary lipid composition experimental and clinical study
Nassuato G, Iemmolo R, Strazzabosco M, Lirussi F, Deana R, Francesconi M, Muraca M, Passera D, Fragasso A, Orlando R, Csomós G, Okolicsányi L. Effect of Silibinin on biliary lipid composition experimental and clinical study. Journal Of Hepatology 1991, 12: 290-295. PMID: 1940257, DOI: 10.1016/0168-8278(91)90829-z.Peer-Reviewed Original ResearchConceptsBiliary lipid compositionBiliary cholesterol concentrationTotal bile salt concentrationBile salt concentrationBile flowBiliary cholesterolCholesterol concentrationsBody weightTotal liver cholesterol contentBile saturation indexSignificant dose-dependent inhibitionEffect of silymarinLiver cholesterol contentEffect of silibininDose-dependent inhibitionCoA reductase activitySilymarin treatmentLiver cholesterolPlacebo administrationCholecystectomized patientsControl ratsClinical studiesLipid compositionSilibinin doseSilibinin